One year of SARS-CoV-2 circulation in the Nouvelle-Aquitaine region, February 2021-2022, France.
France
Nouvelle-Aquitaine
SARS-CoV-2
epidemiological survey
variant
Journal
Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977
Informations de publication
Date de publication:
2023
2023
Historique:
received:
28
02
2023
accepted:
17
07
2023
medline:
14
8
2023
pubmed:
14
8
2023
entrez:
14
8
2023
Statut:
epublish
Résumé
Since 2021, 3 variants of concern (VOC) have spread to France, causing successive epidemic waves. To describe the features of Alpha, Delta and Omicron VOC circulation in the Nouvelle-Aquitaine region, France, between February 2021 and February 2022. Data from the three university hospitals (UH) of Nouvelle-Aquitaine were used to describe regional SARS-CoV-2 circulation (RT-PCR positive rates and identified VOC) as well as its consequences (total number of hospitalizations and admissions in intensive care unit). They were analyzed according to the predominant variant and compared with national data. A total of 611,106 SARS-CoV-2 RT-PCR tests were performed in the 3 Nouvelle-Aquitaine UH during the study period. The 37,750 positive samples were analyzed by variant-specific RT-PCR or whole-genome sequencing. In 2021, Alpha VOC was detected from week 5 until week 35. Delta became the most prevalent variant (77.3%) in week 26, reaching 100% in week 35. It was replaced by Omicron, which was initially detected week 48, represented 77% of positive samples in week 52 and was still predominant in February 2022. The RT-PCR positive rates were 4.3, 4.2, and 21.9% during the Alpha, Delta and Omicron waves, respectively. The ratio between intensive care unit admissions and total hospitalizations was lower during the Omicron wave than during the two previous waves due to the Alpha and Delta variants. This study highlighted the need for strong regional cooperation to achieve effective SARS-CoV-2 epidemiological surveillance, in close association with the public health authorities.
Sections du résumé
Background
UNASSIGNED
Since 2021, 3 variants of concern (VOC) have spread to France, causing successive epidemic waves.
Objectives
UNASSIGNED
To describe the features of Alpha, Delta and Omicron VOC circulation in the Nouvelle-Aquitaine region, France, between February 2021 and February 2022.
Study design
UNASSIGNED
Data from the three university hospitals (UH) of Nouvelle-Aquitaine were used to describe regional SARS-CoV-2 circulation (RT-PCR positive rates and identified VOC) as well as its consequences (total number of hospitalizations and admissions in intensive care unit). They were analyzed according to the predominant variant and compared with national data.
Results
UNASSIGNED
A total of 611,106 SARS-CoV-2 RT-PCR tests were performed in the 3 Nouvelle-Aquitaine UH during the study period. The 37,750 positive samples were analyzed by variant-specific RT-PCR or whole-genome sequencing. In 2021, Alpha VOC was detected from week 5 until week 35. Delta became the most prevalent variant (77.3%) in week 26, reaching 100% in week 35. It was replaced by Omicron, which was initially detected week 48, represented 77% of positive samples in week 52 and was still predominant in February 2022. The RT-PCR positive rates were 4.3, 4.2, and 21.9% during the Alpha, Delta and Omicron waves, respectively. The ratio between intensive care unit admissions and total hospitalizations was lower during the Omicron wave than during the two previous waves due to the Alpha and Delta variants.
Conclusion
UNASSIGNED
This study highlighted the need for strong regional cooperation to achieve effective SARS-CoV-2 epidemiological surveillance, in close association with the public health authorities.
Identifiants
pubmed: 37577437
doi: 10.3389/fmicb.2023.1176575
pmc: PMC10420073
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1176575Informations de copyright
Copyright © 2023 Deroche, Bellecave, David, Ouattara, Garcia, Roblot, Boinot, Faucher, Rejasse, Gschwind, Malvy, Filleul, Rogez, Lévêque and Lafon.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Emerg Infect Dis. 2021 Nov;27(11):2802-2809
pubmed: 34388358
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
Euro Surveill. 2021 Mar;26(9):
pubmed: 33663644
Virus Evol. 2021 Jul 30;7(2):veab064
pubmed: 34527285
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Sci Rep. 2022 Mar 21;12(1):4796
pubmed: 35314722
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
Nat Commun. 2022 May 18;13(1):2745
pubmed: 35585202
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Sci Transl Med. 2022 Jul 6;14(652):eabo5395
pubmed: 35503007
Nat Commun. 2022 Oct 23;13(1):6316
pubmed: 36274062
Euro Surveill. 2021 Apr;26(13):
pubmed: 33797392
Nat Commun. 2022 Feb 8;13(1):751
pubmed: 35136068
Clin Microbiol Infect. 2022 Nov;28(11):1503.e5-1503.e8
pubmed: 35792280
Science. 2021 Apr 9;372(6538):
pubmed: 33658326
Science. 2021 Nov 19;374(6570):995-999
pubmed: 34648303
Lancet Infect Dis. 2022 Jan;22(1):35-42
pubmed: 34461056